Table 2.
Correlation between clinical and pathological variables and PDK1, PDK2, PDK3 and PDK4 protein expression in prostate cancer.
| Patients – no. | N = 120 | PDK1 negative | PDK1 positive | PDK2 negative | PDK2 positive | PDK3 negative | PDK3 positive | PDK4 negative | PDK4 positive |
|---|---|---|---|---|---|---|---|---|---|
| (N = 26) | (N = 89) | (N = 17) | (N = 102) | (N = 13) | (N = 100) | (N = 14) | (N = 96) | ||
| Median follow-up time (IQR) – year | 120 | ρ = -0.180 / P = 0.295 | ρ = 0.080 / P = 0.580 | ρ = 0.006 / P = 0.592 | ρ = -0.315 / P = 0.016 | ||||
| 10.5 (9.8-12.4) | 12 (8.4-14.9) | 10.3 (1-16) | 10 (2-14) | 10.5 (1-16) | 10.2 (9.4-13.9) | 10.5 (1-16) | 13.2 (1-15) | 10.3 (2.1-16) | |
| Median age at surgery (IQR) – year | ρ = 0.097 / P = 0.632 | ρ = -0.112 / P = 0.603 | ρ = 0.035 / P = 0.065 | ρ = 0.019 / P = 0.834 | |||||
| 63 (59-68) | 62 (50-73) | 63 (48-71) | 64 (54-73) | 63 (48-71) | 61 (52-73) | 63 (48-71) | 62 (52-71) | 63 (48-73) | |
| Age at surgery – no. (%) | ρ = 0.046 / P = 0.625 | ρ = -0.108 / P = 0.237 | ρ = 0.022 / P = 0.817 | ρ = 0.041 / P = 0.668 | |||||
| < 65 year | 78 (65) | 18 (69) | 57 (64) | 9 (53) | 69 (68) | 9 (69) | 66 (66) | 10 (71) | 63 (66) |
| > 65 year | 42 (35) | 8 (31) | 32 (36) | 8 (47) | 33 (32) | 4 (31) | 34 (34) | 4 (29) | 33 (34) |
| Preoperative PSA – no. (%) | ρ = 0047 / P = 0.305 | ρ = 0.020 / P = 0.875 | ρ = -0.056 / P = 0.715 | ρ = 0.109 / P = 0.280 | |||||
| ≤ 6 ng/ml | 36 (30) | 10 (38.5) | 26 (29) | 5 (29.5) | 31 (30.5) | 4 (31) | 32 (32) | 7 (50) | 29 (30) |
| > 6 ng/ml and ≤ 10 ng/ml | 43 (35) | 6 (23) | 34 (38) | 6 (35) | 36 (35) | 3 (23) | 36 (36) | 2 (14) | 34 (36) |
| > 10 ng/ml and ≤ 20 ng/ml | 33 (27.5) | 9 (34.5) | 23(26) | 5 (29.5) | 28 (27.5) | 4 (31) | 27 (27) | 4 (29) | 27 (28) |
| > 20 ng/ml | 4 (3.3) | 0 (0) | 4 (5) | 0 (0) | 4 (4) | 1 (7.5) | 3 (3) | 0 (0) | 4 (4) |
| Missing | 4 (3.3) | 1 (4) | 2 (2) | 1 (6) | 3 (3) | 1 (7.5) | 2 (2) | 1 (7) | 2 (2) |
| Gleason grade – no. (%) | ρ = 0.179 / P = 0.056 | ρ = 0.092 / P = 0.617 | ρ = 0.042 / P = 0.839 | ρ = 0.075 / P = 0.199 | |||||
| ≤ 6 | 72 (60) | 19 (73) | 51 (57) | 12 (70) | 59 (58) | 8 (62) | 61 (61) | 8 (57) | 60 (62.5) |
| 3+4 | 22 (18) | 4 (15.5) | 17 (19) | 3 (18) | 19 (18) | 3 (23) | 18 (18) | 5 (36) | 16 (16.5) |
| 4+3 | 7 (6) | 3 (11.5) | 4 (5) | 0 (0) | 7 (7) | 1 (7.5) | 5 (5) | 1 (7) | 5 (5) |
| ≥ 8 | 19 (16) | 0 (0) | 17 (19) | 2 (12) | 17 (17) | 1 (7.5) | 16 (16) | 0 (0) | 15 (16) |
| Stage - no. (%) | ρ = 0.083 / P = 0.371 | ρ = 0.000 / P = 1 | ρ = 0.095 / P = 0.315 | ρ = 0.107 / P = 0.243 | |||||
| T2 | 99 (82.5) | 23 (88.5) | 72 (81) | 14 (82) | 84 (82) | 12 (92) | 81 (81) | 14 (100) | 77 (80) |
| T3 | 21 (17.5) | 3 (11.5) | 17 (19) | 3 (18) | 18 (18) | 1 (8) | 19 (19) | 0 (0) | 19 (20) |
| Surgical margins – no. (%) | ρ = -0.042 / P = 0.654 | ρ = -0.007 / P = 0.937 | ρ = 0.022 / P = 0.817 | ρ = -0.132 / P = 0.165 | |||||
| Negative | 78 (65) | 16 (61.5) | 59 (66) | 11 (65) | 67 (66) | 9 (69) | 66 (66) | 7 (50) | 66 (69) |
| Positive | 42 (35) | 10 (38.5) | 30 (34) | 6 (35) | 35 (34) | 4 (31) | 34 (34) | 7 (50) | 30 (31) |
| Extracapsular extension– no. (%) | ρ = 0.073 / P = 0.437 | ρ = -0.009 / P = 0.921 | ρ = 0.088 / P = 0.350 | ρ = 0.169 / P = 0.076 | |||||
| No | 100 (83) | 23 (88) | 73 (82) | 14 (82) | 85 (83) | 12 (92) | 82 (82) | 14 (100) | 78 (81) |
| Yes | 20 (17) | 3 (12) | 16 (18) | 3 (18) | 17 (17) | 1 (8) | 18 (18) | 0 (0) | 18 (19) |
| Seminal vesicle invasion – no. (%) | ρ = -0.011 / P = 0.907 | ρ = 0.085 / P = 0.351 | ρ = -0.081 / P = 0.389 | ρ = 0.074 / P = 0.437 | |||||
| No | 20 (17) | 25 (96) | 86 (96) | 17 (100) | 97 (95) | 12 (92) | 97 (97) | 14 (100) | 92 (96) |
| Yes | 100 (83) | 1 (4) | 3 (4) | 0 (0) | 5 (5) | 1 (8) | 3 (3) | 0 (0) | 4 (4) |
| CAPRA-S risk group – no. (%)* | ρ = 0.085 / P = 0.492 | ρ = 0.180 / P = 0.197 | ρ = 0.032 / P = 0.817 | ρ = 0.032 / P = 0.544 | |||||
| Low | 48 (40) | 13 (50) | 32 (36) | 10 (59) | 38 (37) | 6 (46) | 39 (39) | 6 (43) | 38 (40) |
| Intermediate | 44 (37) | 8 (31) | 36 (40) | 5 (29) | 38 (37) | 4 (31) | 39 (39) | 7 (50) | 35 (36) |
| High | 9 (8) | 2 (7.5) | 6 (7) | 0 (0) | 9 (9) | 1 (7.5) | 6 (6) | 0 (0) | 6 (6) |
| Missing | 19 (15) | 3 (11.5) | 15 (17) | 2 (12) | 17 (17) | 2 (15.5) | 16 (16) | 1 (7) | 17 (18) |
| Biochemical recurrence – no. (%) | ρ = 0.142 / P = 0.128 | ρ = 0.195 / P = 0.033 | ρ = 0.028 / P = 0.763 | ρ = 0.163 / P = 0.088 | |||||
| Negative | 78 (65) | 20 (77) | 54 (61) | 15 (88) | 63 (62) | 9 (69) | 65 (65) | 12 (86) | 60 (62.5) |
| Positve | 42 (35) | 6 (23) | 35 (39) | 2 (12) | 39 (38) | 4 (31) | 35 (35) | 2 (14) | 36 (37.5) |
| Disease-free survival – no. (%) | ρ = -0.141 / P = 0.168 | ρ = -0.202 / P = 0.045 | ρ = -0.030 / P = 0.770 | ρ = -0.170 / P = 0.106 | |||||
| Yes | 41 (34) | 6 (23) | 34 (38) | 2 (12) | 38 (37) | 4 (31) | 34 (34) | 2 (14) | 35 (36) |
| No | 58 (48) | 15 (58) | 42 (47) | 11 (65) | 47 (46) | 7 (53.5) | 39 (39) | 9 (64) | 45 (47) |
| Missing | 21 (18) | 5 (19) | 13 (15) | 4 (23) | 17 (17) | 2 (15.5) | 27 (27) | 3 (22) | 16 (17) |
*The CAPRA-S scores were categorized to give the three risk groups: Low risk if sscore 0-2; Intermediate risk if score 3 to 5; High risk if score 6 to 12.
Spearsman´s correlation ρ (95% CI) / P value.
IQR, interquartile range; PSA, prostate-specific antigen; AR, androgen receptor.